RU2009133336A - Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами - Google Patents

Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами Download PDF

Info

Publication number
RU2009133336A
RU2009133336A RU2009133336/04A RU2009133336A RU2009133336A RU 2009133336 A RU2009133336 A RU 2009133336A RU 2009133336/04 A RU2009133336/04 A RU 2009133336/04A RU 2009133336 A RU2009133336 A RU 2009133336A RU 2009133336 A RU2009133336 A RU 2009133336A
Authority
RU
Russia
Prior art keywords
optionally substituted
heteroaryl
heterocyclyl
haloalkyl
aryl
Prior art date
Application number
RU2009133336/04A
Other languages
English (en)
Russian (ru)
Inventor
Шифэн ЛЮ (CA)
Шифэн ЛЮ
Цзяньминь ФУ (CA)
Цзяньминь Фу
Раджендер КАМБОДЖ (CA)
Раджендер Камбодж
Ци ЦЗЯ (CA)
Ци Цзя
Марк ВУД (CA)
Марк ВУД
Султан ЧОВДХУРИ (CA)
Султан ЧОВДХУРИ
Цзяниу СУНЬ (CA)
Цзяниу СУНЬ
Original Assignee
Ксенон Фармасьютикалз Инк. (Ca)
Ксенон Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксенон Фармасьютикалз Инк. (Ca), Ксенон Фармасьютикалз Инк. filed Critical Ксенон Фармасьютикалз Инк. (Ca)
Publication of RU2009133336A publication Critical patent/RU2009133336A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2009133336/04A 2007-02-05 2008-02-05 Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами RU2009133336A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88825307P 2007-02-05 2007-02-05
US60/888,253 2007-02-05
US91212207P 2007-04-16 2007-04-16
US60/912,122 2007-04-16

Publications (1)

Publication Number Publication Date
RU2009133336A true RU2009133336A (ru) 2011-03-20

Family

ID=39420569

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009133336/04A RU2009133336A (ru) 2007-02-05 2008-02-05 Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами

Country Status (12)

Country Link
US (1) US20080194616A1 (enExample)
EP (1) EP2079737A1 (enExample)
JP (1) JP2010518026A (enExample)
AR (1) AR065194A1 (enExample)
AU (1) AU2008213836A1 (enExample)
BR (1) BRPI0807351A2 (enExample)
CA (1) CA2677493A1 (enExample)
CL (1) CL2008000369A1 (enExample)
MX (1) MX2009008338A (enExample)
RU (1) RU2009133336A (enExample)
TW (1) TW200838539A (enExample)
WO (1) WO2008097991A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2120919T3 (da) * 2006-12-18 2012-11-26 Cardoz Ab Ny kombination til anvendelse ved behandling af inflammatoriske lidelser
AU2007336077A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
EP2229388A4 (en) * 2008-01-11 2012-03-07 Glenmark Pharmaceuticals Sa CONDENSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
WO2009125168A1 (en) * 2008-04-07 2009-10-15 Cardoz Ab New combination for use in the treatment of inflammatory disorders
US8119647B2 (en) * 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
MX2014005297A (es) 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
WO2013115884A2 (en) * 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104718188B (zh) * 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
MX2015000164A (es) 2012-07-06 2015-08-12 Genentech Inc Benzamidas n-sustituidas y metodos para usarlas.
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2015038533A2 (en) * 2013-09-10 2015-03-19 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
AU2016248886B2 (en) * 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
CN107847765B (zh) 2015-06-18 2021-05-04 89生物有限公司 1,4-取代的哌啶衍生物
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
CR20180242A (es) 2015-09-28 2018-08-10 Genentech Inc Compuestos terapéuticos y sus métodos de uso
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
WO2019236694A1 (en) * 2018-06-05 2019-12-12 Incarda Therapeutics, Inc. Methods for diagnosing brugada syndrome using an aerosol
JP7638987B2 (ja) * 2019-11-25 2025-03-04 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物、及び使用法
CN110818709B (zh) * 2019-11-28 2022-09-02 成都大学 一种co2参与下合成嘧啶酮类化合物的方法
CN113292557B (zh) * 2021-05-31 2022-02-11 贵州大学 一种含吲哚单元的吡啶并嘧啶酮类介离子衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63112566A (ja) * 1986-10-28 1988-05-17 Nissan Chem Ind Ltd ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤
CN1871008A (zh) * 2003-10-21 2006-11-29 默克公司 用于治疗神经病变性疼痛的三唑并－哒嗪化合物和它们的衍生物
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
MX2007016270A (es) * 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
JP5094725B2 (ja) * 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
EP1818058A3 (en) * 2006-02-13 2007-11-07 Astion Pharma A/S Treatment of mmp-mediated dermatological diseases with pemirolast

Also Published As

Publication number Publication date
WO2008097991A1 (en) 2008-08-14
CL2008000369A1 (es) 2008-04-18
EP2079737A1 (en) 2009-07-22
MX2009008338A (es) 2009-08-12
AR065194A1 (es) 2009-05-20
AU2008213836A1 (en) 2008-08-14
BRPI0807351A2 (pt) 2014-05-20
TW200838539A (en) 2008-10-01
US20080194616A1 (en) 2008-08-14
CA2677493A1 (en) 2008-08-14
JP2010518026A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
RU2009133336A (ru) Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами
JP2010518026A5 (enExample)
JP6893271B2 (ja) キナーゼ阻害剤である複素環式アミド
US11718588B2 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
ES2548135T3 (es) Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
TWI617552B (zh) 用於激酶調節及其適應症之化合物及方法
KR20230127371A (ko) 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
AU2015298378B2 (en) Imidazopyridazine compounds
JP2018527398A (ja) ヘテロ環式化合物およびそれらの使用
JP2022536540A (ja) アミノピリミジンアミドオートファジー阻害剤およびその使用方法
AU2015365465A1 (en) Amido thiadiazole derivatives as NADPH Oxidase inhibitors
PT1740584E (pt) Derivado de quinolina fundida e sua utilização
WO2011021678A1 (ja) 縮合複素環化合物
JP2022502370A (ja) 置換ピリジニル化合物およびその使用
JP2023529884A (ja) コラーゲン１翻訳阻害剤及びその使用方法
US20200123147A1 (en) Thiazole compounds useful as prmt5 inhibitors
EA036318B1 (ru) 6-аминопиридин-3-илтиазолы в качестве модуляторов rort
WO2020203610A1 (ja) 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
JPWO2020017569A1 (ja) Ｔ型カルシウムチャネル阻害剤
US20190062274A1 (en) Heterocyclic compound
US7795267B2 (en) Bicyclic piperazine compound having TGR23 antagonistic activity
WO2011030798A1 (ja) ８－オキソジヒドロプリン誘導体
JP2024502106A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用
US20230348369A1 (en) Nampt modulators
US20240279215A1 (en) Nampt modulators